Beta3 Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure
Status:
Unknown status
Trial end date:
2019-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of mirabegron (a B3
adrenergic receptor agonist) in patients with pulmonary hypertension secondary to heart
failure by conducting a randomized multicenter phase II placebo-controlled clinical trial.
Phase:
Phase 2
Details
Lead Sponsor:
Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III
Collaborators:
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau Hospital Clinic of Barcelona Hospital Universitario 12 de Octubre Puerta de Hierro University Hospital